BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10884803)

  • 1. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of apoptotic and proliferation markers in meningiomas.
    Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
    J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of cathepsin D in meningiomas.
    Castilla EA; Prayson RA; Abramovich CM; Cohen ML
    Am J Clin Pathol; 2003 Jan; 119(1):123-8. PubMed ID: 12520707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery for convexity meningiomas.
    Morokoff AP; Zauberman J; Black PM
    Neurosurgery; 2008 Sep; 63(3):427-33; discussion 433-4. PubMed ID: 18812953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
    Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
    Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
    Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
    Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
    Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
    No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence and regrowth of benign meningiomas.
    Nakasu S; Fukami T; Jito J; Nozaki K
    Brain Tumor Pathol; 2009; 26(2):69-72. PubMed ID: 19856217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas.
    Konstantinidou AE; Givalos N; Gakiopoulou H; Korkolopoulou P; Kotsiakis X; Boviatsis E; Agrogiannis G; Mahera H; Patsouris E
    Apoptosis; 2007 Apr; 12(4):695-705. PubMed ID: 17143787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas.
    Takei H; Buckleair LW; Powell SZ
    Neuropathology; 2008 Feb; 28(1):62-8. PubMed ID: 18021195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.